Fixing The FDA's Orange Book

被引：1
|
作者：
Hemphill, C. Scott [1 ]
Sampat, Bhaven N. [2 ]
机构：
[1] NYU, New York, NY USA
[2] Columbia Univ, New York, NY 10027 USA
来源：
HEALTH AFFAIRS | 2022年 / 41卷 / 06期
基金：
美国国家科学基金会; 欧洲研究理事会;
关键词：
PATENTS;
D O I：
10.1377/hlthaff.2022.00369
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
The modern regime for balancing innovation and competition in pharmaceuticals was established through the Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch Waxman Act. This regime needs updating. The process that Hatch Waxman established for listing patents and challenging patents on the Food and Drug Administration's Orange Book is one important area for reform.
引用
收藏
页码：797 / 800
页数：4
相关论文
共 50 条
  • [1] Recent Developments in the Listing of Patents in FDA's Orange Book
    Holman, Christopher M.
    [J]. BIOTECHNOLOGY LAW REPORT, 2023, 42 (04) : 168 - 183
  • [2] CHAL 7 - The first step to ANDA litigation: Orange Book listability with the FDA
    Irving, Thomas L.
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 237 : 944 - 944
  • [3] The Orange Book
    Laurie L. Hill
    [J]. Nature Reviews Drug Discovery, 2005, 4 : 621 - 621
  • [4] FIXING THE BOOK REVIEW
    Fleming, James Rodger
    [J]. BULLETIN OF THE AMERICAN METEOROLOGICAL SOCIETY, 2011, 92 (12) : 1570 - 1570
  • [5] The Orange Book
    Hill, LL
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2005, 4 (08) : 621 - 621
  • [6] The NBER Orange Book Dataset: A user's guide
    Durvasula, Maya
    Hemphill, C. Scott
    Ouellette, Lisa Larrimore
    Sampat, Bhaven
    Williams, Heidi L.
    [J]. RESEARCH POLICY, 2023, 52 (07)
  • [7] Will purple become the new orange? The new FDA purple book for biologics: what does the future hold?
    Sabatelli, Anthony D.
    Alpha-Cobb, Cambria J.
    [J]. PHARMACEUTICAL PATENT ANALYST, 2015, 4 (02) : 63 - 68
  • [8] Electronic "Orange book"
    Nightingale, SL
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (17): : 1580 - 1580
  • [9] A Comprehensive Analysis of Biopharmaceutical Products Listed in the FDA's Purple Book
    Chen, Fuduan
    Zhong, Hao
    Chan, Ging
    Ouyang, Defang
    [J]. AAPS PHARMSCITECH, 2024, 25 (05)
  • [10] THE ORANGE BOOK: RECLAIMING LIBERALISM
    Meadowcroft, John
    [J]. ECONOMIC AFFAIRS, 2005, 25 (04) : 86 - 86
12345